Latest Headlines

  1. 20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm From The University Of South Carolina 5/12/2026

    20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive, worldwide licensing agreement with the University of South Carolina to commercialize a patented algorithm developed by a team headed by James Hébert, Sc.D., Director of the South Carolina Statewide Cancer Prevention and Control Program and Health Sciences Distinguished Professor in the Department of Epidemiology and Biostatistics.

  2. Reliable, High-Performance Pump For HPLC And UHPLC 5/12/2026

    All models of the ASI 540 pump range feature an intuitive touchscreen display that enables full control of the pump functions, flow rates, and gradient programs. 

  3. Amcor Achieves CNAS Accreditation In China, Speeding Customer Access To Global Markets 5/11/2026

    Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced that its Asia Pacific Innovation Center (APIC) laboratory has received accreditation from the China National Accreditation Service for Conformity Assessment (CNAS), strengthening its role within Amcor's innovation ecosystem.

  4. Caris Life Sciences Submits Application To New York State Department Of Health For Caris Assure Blood Based Testing Authorization 5/8/2026

    Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State.

  5. Skoltech Scientists Uncover The Secret Of A Persistent Laboratory Pest And Find A Way To Protect Against It 5/7/2026

    Researchers from Skoltech (part of the VEB.RF Group) have uncovered the molecular mechanisms that make one of the most persistent laboratory contaminants — bacteriophage T1 — unusually resilient and dangerous to bacterial cultures. 

  6. Mayo Clinic And Stanford Researchers Develop First Blood Test To Map Tumor 'Neighborhoods,' Improving Prediction Of Therapy Response 5/6/2026

    Mayo Clinic and Stanford Medicine researchers have developed the first blood test to map the complex ecosystem surrounding cancer cells, offering a more accurate way to predict which patients will benefit from immunotherapy.

  7. Lucent Diagnostics Announces Collaboration With Tempus To Integrate Blood-Based Alzheimer's Biomarker Testing Into Clinical Workflows 5/6/2026

    Lucent Diagnostics, a brand of Quanterix Corporation, today announced a collaboration with Tempus AI Inc, a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer’s disease.

  8. MLM Medical Labs Launches Electronic Requisition Solution To Reduce Errors, Simplify Workflows And Accelerate Timelines 5/6/2026

    MLM Medical Labs (MLM), a leading central and specialty laboratory supporting global clinical trials, today announced the launch of its Electronic Requisition (e-Requisition) solution, designed to address one of the most persistent challenges in clinical trials: incomplete, inaccurate, and delayed sample data originating at the clinical trial site.

  9. PathAI And A.C.Camargo Cancer Center Announce Cooperation To Expand Digital Pathology With AI In Brazil Via SUS 5/5/2026

    PathAI, a global leader in AI-powered digital pathology solutions, and A.C.Camargo Cancer Center, a national benchmark in oncological treatment, education, and research, are joining forces strategically to support the adoption of digital and AI-enabled pathology across Brazil.

  10. arcoris bio Launches ImmunoMUSE, Enabling Flexible, High-Sensitivity Multiplex Immunofluorescence With User-Defined Antibodies 5/5/2026

    arcoris bio, a Swiss life science research tools and in vitro diagnostics company, today announced the launch of its immunoMUSE kits, based on its breakthrough MUSE biomarker detection platform.